Literature DB >> 24752265

Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage.

Gisele Peirano1, Akke K van der Bij2, Joshua L Freeman3, Laurent Poirel4, Patrice Nordmann4, Michael Costello5, Veronika L Tchesnokova6, Johann D D Pitout7.   

Abstract

We designed a study to describe the characteristics of sequence type 131 (ST131) lineages, including the H30-Rx sublineage, among a global collection of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolates from 9 countries collected from 2000 to 2011. A total of 240 nonrepeat isolates from Canada, the United States, Brazil, the Netherlands, France, the United Arab Emirates (UAE), India, South Africa, and New Zealand were included. Established PCR, sequencing, and typing methods were used to define ST131 lineages, H30 and H30-Rx phylogenetic groups, gyrA and parC mutations, virotypes, and plasmid-mediated quinolone resistance determinants. The majority of the isolates produced CTX-M-15 with aac(6')-lb-cr, belonged to phylogenetic group B2, and were positive for the H30 lineage with the gyrA1AB and parC1aAB mutations. ST131 showed 15 distinct pulsotypes; 43% of the isolates belonged to four pulsotypes, with a global distribution. Seventy-five percent of the ST131 isolates belonged to H30-Rx; this sublineage was present in all the countries and was associated with multidrug resistance, blaCTX-M-15, aac(6')-lb-cr, and virotypes A and C. The H41 lineage was negative for the ST131 pabB allele-specific PCR. The multidrug-resistant H30-Rx sublineage poses an important public health threat due to its global distribution, association with virotype C, and high prevalence among ST131 isolates that produce CTX-M-15.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24752265      PMCID: PMC4068522          DOI: 10.1128/AAC.02428-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

Authors:  Johann D D Pitout; Kevin B Laupland
Journal:  Lancet Infect Dis       Date:  2008-03       Impact factor: 25.071

2.  Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals.

Authors:  Gisele Peirano; Mike Costello; Johann D D Pitout
Journal:  Int J Antimicrob Agents       Date:  2010-03-31       Impact factor: 5.283

3.  Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131.

Authors:  James R Johnson; Olivier Clermont; Brian Johnston; Connie Clabots; Veronika Tchesnokova; Evgeni Sokurenko; Adam F Junka; Beata Maczynska; Erick Denamur
Journal:  J Clin Microbiol       Date:  2014-02-05       Impact factor: 5.948

4.  Clinical and molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli causing bacteremia in the Rotterdam Area, Netherlands.

Authors:  Akke K van der Bij; Gisele Peirano; Wil H F Goessens; Eric R van der Vorm; M van Westreenen; Johann D D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

5.  Characteristics of infections caused by extended-spectrum β-lactamase-producing Escherichia coli from community hospitals in South Africa.

Authors:  Gisele Peirano; Cornelius H J van Greune; Johann D D Pitout
Journal:  Diagn Microbiol Infect Dis       Date:  2011-04       Impact factor: 2.803

6.  Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections.

Authors:  Johann D D Pitout; Daniel B Gregson; Lorraine Campbell; Kevin B Laupland
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

7.  Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004.

Authors:  James R Johnson; Megan Menard; Brian Johnston; Michael A Kuskowski; Kim Nichol; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

8.  Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains.

Authors:  Olivier Clermont; Hiran Dhanji; Mathew Upton; Tarek Gibreel; Andrew Fox; David Boyd; Michael R Mulvey; Patrice Nordmann; Etienne Ruppé; Jean Louis Sarthou; Thierry Frank; Sophie Vimont; Guillaume Arlet; Catherine Branger; Neil Woodford; Erick Denamur
Journal:  J Antimicrob Chemother       Date:  2009-05-27       Impact factor: 5.790

Review 9.  Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4.

Authors:  Gisele Peirano; Johann D D Pitout
Journal:  Int J Antimicrob Agents       Date:  2010-01-13       Impact factor: 5.283

10.  High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.

Authors:  Gisele Peirano; David Richardson; Jana Nigrin; Allison McGeer; Vivian Loo; Baldwin Toye; Michelle Alfa; Colette Pienaar; Pamela Kibsey; Johann D D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

View more
  41 in total

1.  The Pandemic H30 Subclone of Sequence Type 131 (ST131) as the Leading Cause of Multidrug-Resistant Escherichia coli Infections in the United States (2011-2012).

Authors:  James R Johnson; Stephen Porter; Paul Thuras; Mariana Castanheira
Journal:  Open Forum Infect Dis       Date:  2017-05-02       Impact factor: 3.835

2.  Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.

Authors:  James A Karlowsky; Douglas J Biedenbach; Krystyna M Kazmierczak; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Extensive Genetic Commonality among Wildlife, Wastewater, Community, and Nosocomial Isolates of Escherichia coli Sequence Type 131 (H30R1 and H30Rx Subclones) That Carry blaCTX-M-27 or blaCTX-M-15.

Authors:  Ivana Jamborova; Brian D Johnston; Ivo Papousek; Katerina Kachlikova; Lenka Micenkova; Connie Clabots; Anna Skalova; Katerina Chudejova; Monika Dolejska; Ivan Literak; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  Genetic Features of MCR-1-Producing Colistin-Resistant Escherichia coli Isolates in South Africa.

Authors:  Laurent Poirel; Nicolas Kieffer; Adrian Brink; Jennifer Coetze; Aurélie Jayol; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

5.  Epidemic Emergence in the United States of Escherichia coli Sequence Type 131-H30 (ST131-H30), 2000 to 2009.

Authors:  James R Johnson; Stephen Porter; Paul Thuras; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 6.  The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae.

Authors:  Amy J Mathers; Gisele Peirano; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 7.  Plasmid-mediated quinolone resistance in Enterobacteriaceae: a systematic review with a focus on Mediterranean countries.

Authors:  B Yanat; J-M Rodríguez-Martínez; A Touati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-26       Impact factor: 3.267

8.  Genomic Analysis of Multidrug-Resistant Escherichia coli from North Carolina Community Hospitals: Ongoing Circulation of CTX-M-Producing ST131-H30Rx and ST131-H30R1 Strains.

Authors:  Hajime Kanamori; Christian M Parobek; Jonathan J Juliano; James R Johnson; Brian D Johnston; Timothy J Johnson; David J Weber; William A Rutala; Deverick J Anderson
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

9.  Isolation and Characterization of Escherichia coli Sequence Type 131 and Other Antimicrobial-Resistant Gram-Negative Bacilli from Clinical Stool Samples from Veterans.

Authors:  Muhanad Mohamed; Connie Clabots; Stephen B Porter; Paul Thuras; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

10.  [Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia].

Authors:  Victor M Blanco; Juan J Maya; Adriana Correa; Marcela Perenguez; Juan S Muñoz; Gabriel Motoa; Christian J Pallares; Fernando Rosso; Lorena Matta; Yamile Celis; Martha Garzon; María V Villegas
Journal:  Enferm Infecc Microbiol Clin       Date:  2016-01-13       Impact factor: 1.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.